Untargeted Plasma Metabolomic Profiling in Patients with Major Depressive Disorder Using Ultra-High Performance Liquid Chromatography Coupled with Mass Spectrometry
Major depressive disorder (MDD) is a neuropsychiatric illness with an increasing incidence and a shortfall of efficient diagnostic tools. Interview-based diagnostic tools and clinical examination often lead to misdiagnosis and inefficient systematic treatment selection. Diagnostic and treatment moni...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-07-01
|
| Series: | Metabolites |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-1989/11/7/466 |
| _version_ | 1827687391147589632 |
|---|---|
| author | Claudia Homorogan Diana Nitusca Virgil Enatescu Philip Schubart Corina Moraru Carmen Socaciu Catalin Marian |
| author_facet | Claudia Homorogan Diana Nitusca Virgil Enatescu Philip Schubart Corina Moraru Carmen Socaciu Catalin Marian |
| author_sort | Claudia Homorogan |
| collection | DOAJ |
| description | Major depressive disorder (MDD) is a neuropsychiatric illness with an increasing incidence and a shortfall of efficient diagnostic tools. Interview-based diagnostic tools and clinical examination often lead to misdiagnosis and inefficient systematic treatment selection. Diagnostic and treatment monitoring biomarkers are warranted for MDD. Thus, the emerging field of metabolomics is a promising tool capable of portraying the metabolic repertoire of biomolecules from biological samples in a minimally invasive fashion. Herein, we report an untargeted metabolomic profiling performed in plasma samples of 11 MDD patients, at baseline (MDD1) and at 12 weeks following antidepressant therapy with escitalopram (MDD2), and in 11 healthy controls (C), using ultra-high performance liquid chromatography coupled with electrospray ionization-quadrupole-time of flight-mass spectrometry (UHPLC-QTOF-(ESI+)-MS). We found two putative metabolites ((phosphatidylserine PS (16:0/16:1) and phosphatidic acid PA (18:1/18:0)) as having statistically significant increased levels in plasma samples of MDD1 patients compared to healthy subjects. ROC analysis revealed an AUC value of 0.876 for PS (16:0/16:1), suggesting a potential diagnostic biomarker role. In addition, PS (18:3/20:4) was significantly decreased in MDD2 group compared to MDD1, with AUC value of 0.785. |
| first_indexed | 2024-03-10T09:32:48Z |
| format | Article |
| id | doaj.art-d34c9a986e02451c8bd8b5e6b15ea6ed |
| institution | Directory Open Access Journal |
| issn | 2218-1989 |
| language | English |
| last_indexed | 2024-03-10T09:32:48Z |
| publishDate | 2021-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Metabolites |
| spelling | doaj.art-d34c9a986e02451c8bd8b5e6b15ea6ed2023-11-22T04:23:10ZengMDPI AGMetabolites2218-19892021-07-0111746610.3390/metabo11070466Untargeted Plasma Metabolomic Profiling in Patients with Major Depressive Disorder Using Ultra-High Performance Liquid Chromatography Coupled with Mass SpectrometryClaudia Homorogan0Diana Nitusca1Virgil Enatescu2Philip Schubart3Corina Moraru4Carmen Socaciu5Catalin Marian6Doctoral School, University of Medicine and Pharmacy Victor Babes Timisoara, 300041 Timisoara, RomaniaDepartment of Biochemistry, University of Medicine and Pharmacy Victor Babes Timisoara, 300041 Timisoara, RomaniaDiscipline of Psychiatry, Department of Neurosciences, University of Medicine and Pharmacy Victor Babes Timisoara, 300041 Timisoara, RomaniaDepartment of Biochemistry, University of Medicine and Pharmacy Victor Babes Timisoara, 300041 Timisoara, RomaniaBIODIATECH, Research Center for Applied Biotechnology in Diagnosis and Molecular Therapy, 400478 Cluj-Napoca, RomaniaBIODIATECH, Research Center for Applied Biotechnology in Diagnosis and Molecular Therapy, 400478 Cluj-Napoca, RomaniaDepartment of Biochemistry, University of Medicine and Pharmacy Victor Babes Timisoara, 300041 Timisoara, RomaniaMajor depressive disorder (MDD) is a neuropsychiatric illness with an increasing incidence and a shortfall of efficient diagnostic tools. Interview-based diagnostic tools and clinical examination often lead to misdiagnosis and inefficient systematic treatment selection. Diagnostic and treatment monitoring biomarkers are warranted for MDD. Thus, the emerging field of metabolomics is a promising tool capable of portraying the metabolic repertoire of biomolecules from biological samples in a minimally invasive fashion. Herein, we report an untargeted metabolomic profiling performed in plasma samples of 11 MDD patients, at baseline (MDD1) and at 12 weeks following antidepressant therapy with escitalopram (MDD2), and in 11 healthy controls (C), using ultra-high performance liquid chromatography coupled with electrospray ionization-quadrupole-time of flight-mass spectrometry (UHPLC-QTOF-(ESI+)-MS). We found two putative metabolites ((phosphatidylserine PS (16:0/16:1) and phosphatidic acid PA (18:1/18:0)) as having statistically significant increased levels in plasma samples of MDD1 patients compared to healthy subjects. ROC analysis revealed an AUC value of 0.876 for PS (16:0/16:1), suggesting a potential diagnostic biomarker role. In addition, PS (18:3/20:4) was significantly decreased in MDD2 group compared to MDD1, with AUC value of 0.785.https://www.mdpi.com/2218-1989/11/7/466metabolomicsbiomarkersdepressionlipidsLC-MS |
| spellingShingle | Claudia Homorogan Diana Nitusca Virgil Enatescu Philip Schubart Corina Moraru Carmen Socaciu Catalin Marian Untargeted Plasma Metabolomic Profiling in Patients with Major Depressive Disorder Using Ultra-High Performance Liquid Chromatography Coupled with Mass Spectrometry Metabolites metabolomics biomarkers depression lipids LC-MS |
| title | Untargeted Plasma Metabolomic Profiling in Patients with Major Depressive Disorder Using Ultra-High Performance Liquid Chromatography Coupled with Mass Spectrometry |
| title_full | Untargeted Plasma Metabolomic Profiling in Patients with Major Depressive Disorder Using Ultra-High Performance Liquid Chromatography Coupled with Mass Spectrometry |
| title_fullStr | Untargeted Plasma Metabolomic Profiling in Patients with Major Depressive Disorder Using Ultra-High Performance Liquid Chromatography Coupled with Mass Spectrometry |
| title_full_unstemmed | Untargeted Plasma Metabolomic Profiling in Patients with Major Depressive Disorder Using Ultra-High Performance Liquid Chromatography Coupled with Mass Spectrometry |
| title_short | Untargeted Plasma Metabolomic Profiling in Patients with Major Depressive Disorder Using Ultra-High Performance Liquid Chromatography Coupled with Mass Spectrometry |
| title_sort | untargeted plasma metabolomic profiling in patients with major depressive disorder using ultra high performance liquid chromatography coupled with mass spectrometry |
| topic | metabolomics biomarkers depression lipids LC-MS |
| url | https://www.mdpi.com/2218-1989/11/7/466 |
| work_keys_str_mv | AT claudiahomorogan untargetedplasmametabolomicprofilinginpatientswithmajordepressivedisorderusingultrahighperformanceliquidchromatographycoupledwithmassspectrometry AT diananitusca untargetedplasmametabolomicprofilinginpatientswithmajordepressivedisorderusingultrahighperformanceliquidchromatographycoupledwithmassspectrometry AT virgilenatescu untargetedplasmametabolomicprofilinginpatientswithmajordepressivedisorderusingultrahighperformanceliquidchromatographycoupledwithmassspectrometry AT philipschubart untargetedplasmametabolomicprofilinginpatientswithmajordepressivedisorderusingultrahighperformanceliquidchromatographycoupledwithmassspectrometry AT corinamoraru untargetedplasmametabolomicprofilinginpatientswithmajordepressivedisorderusingultrahighperformanceliquidchromatographycoupledwithmassspectrometry AT carmensocaciu untargetedplasmametabolomicprofilinginpatientswithmajordepressivedisorderusingultrahighperformanceliquidchromatographycoupledwithmassspectrometry AT catalinmarian untargetedplasmametabolomicprofilinginpatientswithmajordepressivedisorderusingultrahighperformanceliquidchromatographycoupledwithmassspectrometry |